Monitoring response to disease-modifying treatment in multiple sclerosis

Standard criteria for defining suboptimal response to disease-modifying treatment (DMT) in patients with multiple sclerosis (MS) are lacking. Decision-making on how and when DMTs should be switched is challenging. The objective of the study was to identify areas of agreement on which and when specific assessments should be conducted to monitor patient response to DMT.